Evolocumab (Repatha) for the treatment of hypercholesterolemia and mixed dyslipidemia

Introduction

Evolocumab (trade name: Repatha) has been approved in Germany since July 2015 for the treatment of hypercholesterolemia or mixed dyslipidemia in adults and teenagers who aren’t able to lower high enough through other medications and diet.

The human body needs cholesterol to work properly. It is needed to produce certain and is an important building block in cell walls. There are two types:

  • “LDL” cholesterol: “LDL” stands for “low-density lipoprotein.” Cholesterol is transported in this form from the liver to where the body needs it. High levels of LDL cholesterol are associated with a higher risk of cardiovascular disease, which is why it is sometimes referred to as “bad” cholesterol.
  • “HDL” cholesterol: “HDL” stands for “high-density lipoprotein.” In this form, cholesterol is transported back to the liver from the body’s organs and tissues. Because high levels of HDL cholesterol are associated with a lower risk of cardiovascular disease, it is sometimes called “good” cholesterol.

Triglycerides also play an important role. They are found in food and are an important source of energy for our body.

People are considered to have hypercholesterolemia (high cholesterol) if their LDL-cholesterol levels are too high. If their triglyceride levels are too high as well, it is known as mixed dyslipidemia. Left untreated, both conditions can lead to arteriosclerosis, and then to cardiovascular diseases such as coronary artery disease. But these levels aren’t the only thing that determine the risk of cardiovascular disease – other individual factors play a role, too.

Evolocumab helps the liver to break down LDL cholesterol, and is supposed to lower the risk of cardiovascular diseases.

Application

Evolocumab is combined with a low-fat diet. It can also be used together with other lipid-lowering drugs. Evolocumab is injected under the skin using a pre-filled pen (140 mg). This can be done either every two weeks at a dose of 140 mg or once a month at a dose of 420 mg (3 pre-filled pens containing 140 mg each).

Other treatments

The standard treatment is a special diet combined with other lipid-lowering drugs or – if the medication and diet are not enough – medication combined with LDL apheresis. This is a special procedure to remove LDL cholesterol from the blood.

Assessment

In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to look into the advantages and disadvantages of evolocumab compared with the standard treatments for hypercholesterolemia or mixed dyslipidemia in adults.

But the manufacturer did not provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of evolocumab (Repatha).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Evolocumab – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A15-38. December 11, 2015. (IQWiG reports; Volume 345).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-19. June 12, 2018. (IQWiG reports; Volume 636).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on July 12, 2018
Next planned update: 2021

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.